Primary Article

Anaplastic Malignant Neoplasms Diagnosis and Treatment

Authors: AGOP Y. BEDIKIAN MD, BRUCE MACKAY MD, MARIO LUNA MD, MANUEL VALDIVIESO MD

Abstract

We studied 35 patients referred to M.D. Anderson Hospital and Tumor Institute with a histologic diagnosis of undifferentiated malignant neoplasms. Further subclassification of the tumors based on elements suggestive of tumor differentiation detected on light and electron microscopic examination was possible in 22 of the 35 patients. The stage of tumor at diagnosis was of prognostic importance. Patients who had localized, surgically resectable disease had significantly longer survival than those with regional tumor invasion or distant tumor metastasis. Patients with metastatic subclassified tumors had response to chemotherapy and survival duration not different from patients with metastatic undifferentiated tumors. The use of multidrug combinations containing cyclophosphamide, doxorubicin HCI (Adriamycin), and dacarbazine (DTIC-Dome) seems to improve the survival of patients with metastatic anaplastic malignant neoplasms.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References